Recent Pfizer Press Releases

  • 2/25/08 2:21 pm EST

    Company Commits to Ensuring Greater Clarity Regarding Spokespeople

    NEW YORK--(BUSINESS WIRE)--Pfizer said today that it is voluntarily withdrawing Lipitor advertising and promotion featuring Dr. Robert Jarvik and committing to ensuring greater clarity in the roles and responsibilities of its spokespeople in its consumer advertising and promotion. Commenting on the withdrawal of the Jarvik advertising and promotion, Pfizer’s President of Worldwide Pharmaceutical Operations Ian Read saidmore...
  • 2/21/08 8:42 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeal of The Hague in the Netherlands has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision prevents Ranbaxy from launching its drug before Lipitor’s basic patent (EP 247,633) expires in November 2011. “Today’s decision ismore...
  • 2/20/08 9:14 am EST

    Acquisition Will Extend Presence in Pulmonary Arterial Hypertension with Product Launched in Several EU Countries; Pfizer Plans Pivotal Trial to Support Registration in the U.S.

    NEW YORK & HOUSTON--(BUSINESS WIRE)--Pfizer Inc today announced that it has entered into an agreement to acquire Encysive Pharmaceuticals Inc. (NASDAQ: ENCY), a publicly held biopharmaceutical company whose product for the treatment of pulmonary arterial hypertension (PAH) is commercially available in much of the European Union and is approved in other markets. Under the terms of the agreement, Pfizer will make a cash tender offer for allmore...
  • 2/19/08 12:00 pm EST

    Pfizer Partners with 15 NGOs to Build Tobacco Control Capacity and Improve Cancer Care and Prevention

    NEW YORK--(BUSINESS WIRE)--The Pfizer Foundation announced today a groundbreaking $33 million multi-year program to address the emerging challenges in cancer and tobacco control. The first round of the Global Health Partnerships grants has already been awarded to 15 non-governmental organizations (NGOs) in 26 countries around the world – from Algeria, China and Japan to Italy, Brazil and Argentina. The program reflects both the Pfizer Foundationmore...
  • 2/13/08 1:00 am EST

    Regulators Meet to Address the Threat of Counterfeit Medicines in Sub-Saharan Africa

    JOHANNESBURG, South Africa--(BUSINESS WIRE)--An international conference to discuss the issue of counterfeit medicines in Africa started this week in Johannesburg. The aim of the conference, which is sponsored by Pfizer, is for representatives from sub-Saharan countries to discuss the threats that counterfeit medicines and unregistered generics pose for the safety of patients in this region and to develop joint plans of action to address this issuemore...
  • 2/6/08 6:00 pm EST

    New Data on Investigational HIV/AIDS Compounds Presented;

    Phase III Data Reinforce Selzentry Efficacy

    BOSTON--(BUSINESS WIRE)--At this week’s major HIV/AIDS research meeting, Pfizer presented new data on two investigational second generation HIV compounds – a CCR5 antagonist and a non-nucleoside reverse transcriptase inhibitor (NNRTI). Pfizer also presented additional data on SelzentryTM (maraviroc) tablets, its first-in-class medicine approved last year for use in treatment-experienced HIV patients infected with a certain type ofmore...
  • 1/28/08 8:10 pm EST

    The First Oral Smoking Cessation Aid in Japan

    TOKYO--(BUSINESS WIRE)--Pfizer Japan Inc (headquarter in Shibuya-ku, Tokyo; headed by President & Chief Executive Officer, Hiromitsu Iwasaki; and capitalized at Yen 64.8 billion) announced that on January 25, the company received manufacturing and marketing authorization for Champix® Tablet 0.5 mg/1mg (varenicline tartrate), a smoking cessation aid for smokers dependent on nicotine. Champix is Japan’s first oral smokingmore...
  • 1/23/08 8:00 am EST
    • Fourth-Quarter 2007 Revenues of $13.1 Billion Increased from $12.6 Billion in the Year-Ago Quarter
    • Fourth-Quarter 2007 Reported Diluted EPS of $0.42 Compared with $1.32 in the Year-Ago Quarter, which Included the $1.08 EPS Gain on the Sale of the Consumer Healthcare Business
    • Fourth-Quarter 2007 Adjusted Diluted EPS(1) of $0.52 Increased from $0.43 in the Year-Ago Quarter
    • Full-Year 2007 Revenues of $48.6 Billion Increased from $48.4 Billion in 2006
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE): ($ in millions, except per share amounts)   Fourth Quarter   Full Year   2007   2006   Changemore...
  • 1/22/08 6:00 am EST

    With Millions of U.S. Dogs Overweight or Obese, and Most Owners Unaware of the Problem, Veterinarians Lend Helping Hand With First-Ever National Canine Weight Check This February

    NEW YORK--(BUSINESS WIRE)--As millions of Americans vow to get healthier and stave off illness by making a New Year’s resolution to lose weight, it’s time for dog owners to make a similar pledge for their furry friends. Recent studies indicate that 25 to 40 percent of U.S. dogs – approximately 17 million – are overweight or obese and potentially facing serious health problems. What’s more troubling is thatmore...
  • 1/18/08 11:25 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts being held on Wednesday, March 5, at 8:30a.m. Eastern Standard Time. The purpose of the meeting is to discuss the Company’s strategic direction. Jeffrey B. Kindler, Pfizer chairman and chief executive officer, will host the meeting. To view and listen to the webcast, visit our web sitemore...